Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03893955 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03893955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03893955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 21, 2019
Completion date
March 31, 2027
Enrollment
150 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cancer, metastatic solid tumors, non-small-cell-lung-cancer (nsclc), triple-negative breast cancer (tnbc)